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During the last decade, Enterococcars has evolved as one 
of the most significant nosocomial pathogens, parti- 
cularly as an etiologic agent of nosocomial bloodstream 
infections [1,3]. The increase in incidence of entero- 
coccal infections is a consequence of their broad natural 
and acquired resistance to antimicrobial agents, several 
different reservoirs ofresistant strains, and, in particular, 
the acquisition of resistance to the glycopeptides, some- 
times leaving no therapeutic options in seriously ill 
patients [3]. 
The first clinical isolates of vancomycin-resistant 
enterococci (VRE) were dlscovered in 1986 by Leclercq 
et a l  in France [4] and by Uttley et a1 in the UK [5]. 
Both outbreaks involved both Enterococcus faecalis and 
E. faecium, and the strains demonstrated high-level 
resistance to vancomycin and teicoplanin. 
Four phenotypes of vancomycin resistance, VanA, 
VanB, VanC and VanD, have been reported. Genes 
determining the VanA and VanB phenotypes are usually 
located on transposons that are often plasmid-mediated, 
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Figure 1 RAPD products obtained in  PCR reactions using ERIC1, AP4 and ERICl/AP4 primers. Molecular size markers 
are indicated (Si, h/BstEII; S2, pBR 322/hhpI). Lane 1, isolate 1 (1639); lane 2, isolate 2 (1640); lane 3, isolate 3 (1641). 
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Figure 2 Pulsed-field gel electrophoresis of BglII-digested 
chromosomal DNA from E. faecitrrn isolates. Molecular 
masses (in kilobases) were obtained from bacteriophage 
DNA concatamers (S). Lane 1, isolate 1 (1639); lane 2, 
isolate 2 (1640); lane 3, isolate 3 (1641). 
and their expression is inducible. The VanC type of 
resistance is a natural feature of E. gallinarum and E. 
casselijlavur. Recently, a new glycopeptide resistance 
phenotype, VanD, was described in E. faecium [6-81. 
There were no  reports of VRE in Poland up to the 
end of 1996, when the first strain was isolated from the 
urinary tract of a patient on the hematology ward of 
Gdansk Medical University (data not published). At 
the beginning of 1997, VRE were isolated from three 
patients hospitalized in the same department. The pre- 
sent paper describes characteristics of these first isolates. 
Two of the patients suffered from acute myelo- 
blastic leukemia, and one from chronic myeloblastic 
leukemia. All three received multiple courses of anti- 
biotics, including glycopeptides, as a result of several 
febrile episodes. In two of the cases, VRE were isolated 
from blood, feces and vaginal swabs (the latter two 
indicating colonization). The third patient was only 
colonized with VRE in the gastrointestinal tract (stool 
specimen positive for VRE). 
The isolates were first identified as vancomycin- 
resistant E. faecium in the Department of Clinical 
Bacteriology, Clinical Hospital No. 1 in Gdansk and 
were sent to the National Reference Center for Anti- 
biotic Resistance in Bacteria in the Sera and Vaccines 
Central Research Laboratory for further investigation. 
Identification to the genus level was carried out 
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Figure 3 Products of specific PCR amplification of vanA 
gene. Molecular size markers are indicated. (Sl, h/BstEII; 
SZ, pBR 322/MspI). Lane 1, glycopeptide-susceptible E. 
faecitrrn BM4147-1; lane 2, glycopeptide-resistant 
E.faen'urn BM4147; lane 3, isolate 1 (1639); lane 4, isolate 
2 (1640); lane 5, isolate 3 (1641). 
according to the criteria of Facklam and Collins [9], 
and the species were identified using the rapid ID32 
Strep system (bioMtrieux, Marcy I'Etoile, France). All 
isolates were confirmed to be E. faecium. 
Minimum inhibitory concentrations (MICs) were 
determined by a standard agar dilution procedure 
according to the criteria recommended by the National 
Committee for Clinical Laboratory Standards (NCCLS) 
[lo]. The antimicrobial agents tested were penicillin, 
ampicillin, chloramphenicol, ciprofloxacin, tetracycline, 
streptomycin, gentamicin, vancomycin and teicoplanin. 
The results of the susceptibility testing are listed in 
Table 1. 
The presence of van genes was detected by PCR 
with primers specific for vanA, vanB and vanC genes 
[11,12]. The vunA gene was identified in all strains 
analyzed (Figure 1). The isolates were typed by 
Table 1 Minimal inhibitory concentrations (MICs) (mg/L) 
of three vancomycin-resistant Enterococcus strains 
Isolate 1 Isolate 2 Isolate 3 
Antibiotics (1639) (1 640) (1641) 
~ 
PeniciUln 2512 128 256 
Ampicdin 2256 32 2256 
Tetracycline 0.25 64 64 
Streptomycin 1024 22048 22048 
Gentamcin 16 2048 2048 
Ciprofloxacin 128 128 128 
Teicoplamn 32 64 16 
Vancomycin 256 512 256 
Chloramphenicol 4 8 4 
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genomic DNA restriction fragment length poly- 
morphism (RFLP) analysis using SmaI restriction 
enzyme and a CHEF DRII (BioRad) apparatus for 
PFGE [I?] and by randomly amplified polymorphic 
DNA (RAPD) analysis using ERIC1 and AP4 primers 
[13] (Figures 2 and 3). 
All three E. faecium isolates were found to harbor 
the vanA gene but were genetically unrelated as shown 
by both PFGE (with greater than six bands difference) 
and RAPD (different patterns). Further studies are 
needed in order to identify the source of VRE and the 
routes of their spread among patients. Broad infection 
control measures were proposed for implementation in 
the hospital to limit the spread of VRE. 
It is well known that enterococci constitute a large 
reservoir of resistance genes. This first report of VRE 
in Poland may indicate the potential risk of transferring 
high-level vancomycin resistance to other more virulent 
nosocomial pathogens, thus calling for more stringent 
control over antibiotic usage and for careful monitoring 
of this emerging resistance among enterococci in our 
country. 
References 
1. Moellering R C  Jr. Emergence of enterococcus as a significant 
pathogen. Clin Infect Dis 1992; 14: 1173-8. 
2. Schaberg DR, Culver DH, Gaynes RP. Major trends in the 
microhial etiology of nosocomial infection. Am J Med 1991; 
9 l ( ~ ~ p p l 3 B ) :  S72-5. 
3. Leclercq R. Enterococci acquire new kinds of resistance. Clin 
Infect Dis 1997; 24(suppl 1): S80-4 
4. Leclercq R, Derlot R, Duval J, et al. Plasmid-mediated resistance 
to vancomycin and teicoplanin reslstance in Enterocorclrsfuecium. 
N Engl J Med 1988; 319: 15741. 
5. Uttley AH, George RC,  Naidoo J, et al. High-level vanco- 
mycin-resistant enterococci causing hospital infection. Epidemiol 
Infect 1989; 103: 173-81. 
6. Murray B. Diversity among multidrug-resistant enterococci. 
Emerg Infect Dis 1998; 4: 3747.  
7. Perichon B, Reynolds P, Courvalin P. VanD-type glycopeptide- 
resistant Enterococrtcsfaecium BM4339. Antimicrob Agents Chemo- 
ther 1997; 41: 2016-18. 
8. Leclercq R, Dutka-Malen S, Duval J, et al. Vancomycin 
resistance gene t m C  is specific to Enterocorcus gullinarum. Anti- 
nlicrob Agents Chemother 1992; 36: 2005-8. 
9. Facklam RR, Collins MD. Identification of Enteromrrus species 
isolated from human infections by conventional test scheme. 
J Clin Microbiol 1989; 27: 7314.  
10. National Committee for Clinical Laboratory Standards. Methods 
11 
12 
for dilution antimicrobial susceptibility tests for bacteria that 
grow aerobically, 4th edn. Approved Standard M7-A4. Wayne, 
PA: NCCLS, 1997. 
Dutka-Malen S, Evers S ,  Courvalin P. Detection of glycopeptidr 
resistance genotypes and identification to the species level of 
clinically relevant enterococci by PCR. J Clin Microbiol 1995; 
33: 24-7. 
Clark N, Cooksey R, H d  B, et al. Characterisation of glyco- 
peptide-resistant enterococci from US hospitals. Antimicrob 
Agents Chemother 1993; 37: 231 1-17. 
I 
13. Barbier N,  Saulnier P, Chachaty S, et al. Random amplified 
polymorphic DNA typing versus pulsed-field gel electrophoresis 
for epidemiological typing of vancomycin-resistant enterococci. 
J Clin Microbiol 1996; 34: 1096-9. 
